Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
Mol Oncol. 2017 Sep;11(9):1172-1188. doi: 10.1002/1878-0261.12087. Epub 2017 Jun 26.
Oncogenic signalling via Ca -activated K channels of intermediate conductance (SK4, also known as K 3.1 or IK) has been implicated in different cancer entities including breast cancer. Yet, the role of endogenous SK4 channels for tumorigenesis is unclear. Herein, we generated SK4-negative tumours by crossing SK4-deficient (SK4 KO) mice to the polyoma middle T-antigen (PyMT) and epidermal growth factor receptor 2 (cNeu) breast cancer models in which oncogene expression is driven by the retroviral promoter MMTV. Survival parameters and tumour progression were studied in cancer-prone SK4 KO in comparison with wild-type (WT) mice and in a syngeneic orthotopic mouse model following transplantation of SK4-negative or WT tumour cells. SK4 activity was modulated by genetic or pharmacological means using the SK4 inhibitor TRAM-34 in order to establish the role of breast tumour SK4 for cell growth, electrophysiological signalling, and [Ca ] oscillations. Ablation of SK4 and TRAM-34 treatment reduced the SK4-generated current fraction, growth factor-dependent Ca entry, cell cycle progression and the proliferation rate of MMTV-PyMT tumour cells. In vivo, PyMT oncogene-driven tumorigenesis was only marginally affected by the global lack of SK4, whereas tumour progression was significantly delayed after orthotopic implantation of MMTV-PyMT SK4 KO breast tumour cells. However, overall survival and progression-free survival time in the MMTV-cNeu mouse model were significantly extended in the absence of SK4. Collectively, our data from murine breast cancer models indicate that SK4 activity is crucial for cell cycle control. Thus, the modulation of this channel should be further investigated towards a potential improvement of existing antitumour strategies in human breast cancer.
致癌信号通过中间电导钙激活钾通道 (SK4,也称为 K3.1 或 IK) 已被牵涉到不同的癌症实体中,包括乳腺癌。然而,内源性 SK4 通道对于肿瘤发生的作用尚不清楚。在此,我们通过将 SK4 缺陷型 (SK4 KO) 小鼠与多瘤病毒中间 T 抗原 (PyMT) 和表皮生长因子受体 2 (cNeu) 乳腺癌模型杂交,生成 SK4 阴性肿瘤,在这些模型中,致癌基因的表达受逆转录病毒启动子 MMTV 驱动。我们研究了易患癌症的 SK4 KO 小鼠与野生型 (WT) 小鼠的生存参数和肿瘤进展,并在 SK4 阴性或 WT 肿瘤细胞移植后,在同种异体原位小鼠模型中进行研究。我们使用 SK4 抑制剂 TRAM-34 通过遗传或药理学手段调节 SK4 活性,以确定乳腺癌 SK4 对细胞生长、电生理信号和 [Ca2+] 振荡的作用。SK4 的消融和 TRAM-34 处理减少了 SK4 产生的电流分数、生长因子依赖性 Ca 内流、细胞周期进程和 MMTV-PyMT 肿瘤细胞的增殖率。在体内,SK4 的全局缺失对 PyMT 致癌基因驱动的肿瘤发生的影响很小,而 MMTV-PyMT SK4 KO 乳腺癌肿瘤细胞的原位植入后,肿瘤进展明显延迟。然而,在缺乏 SK4 的情况下,MMTV-cNeu 小鼠模型中的总生存期和无进展生存期显著延长。总之,我们从鼠乳腺癌模型中获得的数据表明,SK4 活性对于细胞周期控制至关重要。因此,应该进一步研究这种通道的调节,以潜在改善人类乳腺癌中的现有抗肿瘤策略。